Grifoxina (Levetiracetam)

Grifoxina is indicated for the treatment of several seizure disorders in patients who require an oral antiepileptic agent.

• Management of partial-onset seizures, with or without secondary generalization.
• Control of generalized tonic-clonic seizures in adults and adolescents.
• Treatment of myoclonic seizures, particularly in juvenile myoclonic epilepsy.
• Adjunctive therapy for refractory epilepsy when other medications are insufficient.
• Use as monotherapy or in combination with other antiepileptic drugs as directed by a healthcare professional.

Levetiracetam may cause a range of side effects, some of which are more frequently observed than others.

Common

• Dizziness or light‑headed feeling.
• Fatigue or generalized tiredness.
• Headache, often mild to moderate.
• Irritability or mood changes.
• Nausea or mild gastrointestinal discomfort.
• Nasal congestion or runny nose.

Serious

• Severe allergic reactions such as rash, swelling, or difficulty breathing.
• Mood disturbances including depression, anxiety, or suicidal thoughts.
• Unusual changes in behavior or aggression.
• Severe skin reactions like Stevens‑Johnson syndrome.
• Hematologic abnormalities such as low blood cell counts.
• Hepatic dysfunction indicated by jaundice or elevated liver enzymes.

Before starting Grifoxina, patients should consider several safety factors and discuss them with their prescriber.

• Review any history of psychiatric disorders, as levetiracetam can affect mood.
• Inform the clinician of any renal impairment; dosage may need adjustment.
• Discuss pregnancy plans, because the safety profile during pregnancy is not fully established.
• Report any signs of allergic reaction promptly.
• Avoid abrupt discontinuation; tapering may be required to prevent seizure worsening.
• Use caution when operating machinery or driving until individual response is known.

Levetiracetam may interact with other medications, influencing its effectiveness or safety.

Avoid

• Concurrent use with strong enzyme‑inducing antiepileptics that may reduce levetiracetam levels.
• Combining with drugs that significantly prolong the QT interval.
• Co‑administration with medications known to cause severe hypersensitivity reactions.

Use with caution

• Other central nervous system depressants, which may increase sedation.
• Antidepressants or antipsychotics, due to potential mood‑related effects.
• Renally cleared drugs, as altered kidney function can affect drug concentrations.
• Hormonal contraceptives, although levetiracetam generally has minimal impact, monitoring is advised.